Xeris Biopharma (NASDAQ:XERS) Insider Sells $103,835.41 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $6.23, for a total value of $103,835.41. Following the completion of the sale, the insider owned 1,193,173 shares in the company, valued at $7,433,467.79. The trade was a 1.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Wednesday, April 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $5.99, for a total value of $99,835.33.
• On Monday, March 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.25, for a total value of $104,168.75.
• On Monday, February 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.45, for a total value of $124,169.15.

Xeris Biopharma Stock Performance

Shares of XERS traded up $0.15 during mid-day trading on Friday, reaching $6.28. The company had a trading volume of 1,410,871 shares, compared to its average volume of 1,852,747. Xeris Biopharma Holdings, Inc. has a 52-week low of $4.26 and a 52-week high of $10.08. The company has a quick ratio of 1.57, a current ratio of 2.19 and a debt-to-equity ratio of 16.10. The stock has a market capitalization of $1.08 billion, a P/E ratio of -627.37 and a beta of 0.77. The stock has a 50 day moving average of $5.93 and a two-hundred day moving average of $7.03.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%. On average, analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Weiss Ratings raised Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a report on Monday, March 2nd. Finally, Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Xeris Biopharma has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at approximately $25,000. AlphaQuest LLC acquired a new stake in Xeris Biopharma during the third quarter worth $35,000. Caitong International Asset Management Co. Ltd increased its stake in Xeris Biopharma by 9,276.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after acquiring an additional 7,421 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Xeris Biopharma by 179.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Xeris Biopharma by 29.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after acquiring an additional 1,820 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.